The processes following immunization with plasmid DNA or mRNA vaccines closely resemble those associated with viral infections; that is, within transfected cells, the encoded proteins are transcribed and translated and presented to the immune system. Hence, the assumption that these vaccines might be especially suitable to fight viral infections and tumors via cell-mediated immunity was obvious.
| INTRODUC TI ON
The processes following immunization with plasmid DNA or mRNA vaccines closely resemble those associated with viral infections; that is, within transfected cells, the encoded proteins are transcribed and translated and presented to the immune system. Hence, the assumption that these vaccines might be especially suitable to fight viral infections and tumors via cell-mediated immunity was obvious.
Indeed, early studies in animal models proved the efficacy of DNA vaccines in eliciting powerful cytotoxic T-cell responses. 1 However, it was also quite early recognized that the characteristic T helper 1 (TH1)-biased immune response alongside with production of IFN-γ by CD4+ and CD8+ T cells elicited by this vaccine type could be utilized for modulating allergic T helper 2 (TH2) reactions, which are accompanied by secretion of the key cytokines IL-4, IL-5, and IL-13, and allergen-specific IgE.
The first studies investigating the anti-allergic potential of DNA vaccines encoding clinically relevant allergens were performed with constructs encoding the major allergens from birch and house-dust mite. In these experiments, it was proven that in animal models immunization with allergen-encoding plasmid DNA itself induces a TH1-biased response, while concomitantly avoiding production of IgE and is even able to counteract an established allergic TH2 reaction in a therapeutic setting. 4 or specific cellular compartments by the addition of certain targeting sequences. 2, [5] [6] [7] Based on findings, which indicate that genetic vaccines might be useful in priming a broad immune response, also prime-boost regimens combining genetic vaccines with protein or viral vectors have been explored. 8 Furthermore, safety issues have been addressed by promoting the "revival" of mRNA vaccines 9 and introducing self-replicating (and thereby selflimiting) DNA and mRNA vaccines based on alphaviral sequences. 10 This review discusses the current status of DNA-and mRNAbased vaccines against type I allergic reactions and provides an overview of recent and most promising concepts tested in the clinics.
| E ARLY APPROACHE S
The first studies investigating the anti-allergic effects of DNA immunization used simple conventional plasmids driving expression by a CMV promoter. Intramuscular immunization of rats with plasmid DNA encoding the house-dust mite allergen Der p 5-induced specific immune responses, but prevented the formation of Der p F I G U R E 1 Optimization strategies for genetic vaccines. Modifications of the genetic sequence encoding the antigen of interest include (A) recoding in order to adapt the codon usage, adjust the GC content, and remove sequences that inhibit efficient translation (B) optimization of 5′ and 3′ UTRs to enhance mRNA stability and translation (C) usage of targeting sequences that shuttle the translated protein into specific cellular compartments (D) use of self-replicating RNAs by incorporating alphavirus replicases and (E) mutations of the antigen itself to influence its immunogenicity and/or allergenicity. Such optimized sequences can be used directly as mRNA vaccines, or expressed from a plasmid DNA vector (pDNA). By choosing different promoters, expression strength and cell specificity can be adjusted. Using minicircle plasmids, unwanted bacterial sequences or antibiotic resistance genes needed for production can be removed from the plasmid backbone. Immunostimulatory CpG-ODN can be covalently linked to an antigen of interest or incorporated in liposomal formulations or viruslike particles (VLP) to enhance their efficacy. Genetic vaccines can be injected intramuscularly (i.m.), intradermally (i.d., also using injection devices like the Biojector ™ 2000) or even applied intranodal. Alternatively, (epi)cutaneous vaccination can be achieved with biolistic devices (gene gun) or using microneedles, with or without additional in vivo electroporation 
| INDUC TI ON OF B LO CK ING I G G BY G ENE TI C VACCINATI ON
In rodents, antibody responses following immunization with genetic vaccines encoding allergens are dominated by the IgG2a subclass, which notably is able to activate complement. This clearly contrasts the situation in humans after SIT or SLIT, which mainly induce IgG4 antibodies lacking the capacity to fix complement. Allergen-specific IgG2a antibodies can subsequently be boosted by exposure to the respective allergen as during sensitization or provocation via the airways. Furthermore, we could demonstrate that once induced, this humoral response type is long-lasting and can be maintained even after repeated challenges with aerosolized allergen. 16 With regard to IgG responses induced against allergens, the term "protective" conforms to the potential to block allergen-IgE interactions. Activation of basophils from mice immunized with a DNA vaccine encoding Bet v 1 was shown to be increased following incubation with the allergen in the absence of antibody-containing plasma, indicative of the presence of blocking IgG. 17 To increase antibody responses in general and to generate blocking antibodies, it has been proposed that-besides efficient leader sequences in the plasmid constructs for secretion of allergen-techniques such as in vivo electroporation should be employed. 18 In vivo electroporation following intramuscular DNA immunization against Der p 2 led to a substantial increase in IgG production, whereas the amount of IFN-γ produced remained unaffected. However, it remains to be elucidated whether this improved humoral response contributes to the observed protective effect. 19 In contrast to rodents, humans in general mount weak (antibody) responses after standard injection of genetic vaccines, most likely due to inefficient cellular uptake. Hence, methods to facilitate in vivo delivery of genetic vaccines have been employed, including gene gun vaccination, which induced protective antibody responses against hepatitis B in human non-responders to conventional immunization. 20 Currently, a clinical study investigating the immunogenicity of a DNA vaccine against hepatitis B combined with in vivo electroporation in subjects with chronic infection is underway (clinicaltrials.gov identifier: NCT02431312). Unexpectedly, also unprotected mRNA was found to elicit powerful humoral and cellular immune responses. 28 Owing to this and their unsurpassed inherent safety features, this type of genetic vaccine has been repeatedly employed in clinical trials mainly in the cancer field. So far, immunotherapy with mRNA has been performed in patients suffering from melanoma, non-small-cell lung cancer, renal cell carcinoma, and prostate cancer. 21, [29] [30] Recently, a protective mRNA vaccine against rabies was successfully tested in healthy subjects. 31 Based on a study demonstrating that immunization with mRNA preferentially induces a TH2-biased T-helper cell polarization, which could only be redirected toward an anti-allergic TH1 response by the addition of adjuvants, 32 , the latter was associated with a TH1 phenotype, while DC targeted vaccination induced reduced levels of IFN-γ production 36,37 but was associated with elevated numbers of CD4 + CD25 + FoxP3 + T cells 37 .
| TAILOR-MADE G ENE TI C VACCINE S
Surprisingly, both TH-1 as well as regulatory T-cell induction were equally efficient in suppressing allergic lung inflammation, highlighting that multiple mechanisms can confer allergy protective immune responses after DNA immunization.
| MIMI CK ING THE HE ALTHY S TATUS
Since the discovery of IL-10-producing T regulatory 1 (Tr1) cells, also in the field of allergen-specific immunotherapy, the main focus was set on this immune cell type, whereas immune modulation toward TH-1 responses has been seen more and more critical. According to the hygiene hypothesis, exposure to a traditional farming environment, that is, contact with farm animals and hay as well as consumption of non-pasteurized milk early in life, protects from development of allergies. 40 Specifically, children exposed to such a diversity of microbial compounds have lower frequencies of asthma, hay fever, and atopic sensitization. 41 Furthermore, the protective "farming effect" also leads to a reduced risk for atopic sensitization in adulthood. 42 Obviously, certain microbial products provide a strong activating stimulus for the innate immune system leading to an immune status counteracting allergic reactions. 41 To investigate the mechanisms underlying the "farming effect" mice bred in a cattle barn or a conventional animal facility were sensitized with allergens via the skin and the resulting immune responses were analyzed. 43 Compared to the conventionally raised animals, the farm mice developed an elevated number of activated CD4+ T cells early in life.
Their cytokine profile was skewed toward IL-17 and IL-22 accompanied by increased IL-10 secretion. It was concluded that the farming environment provides a strong, allergy protective IL-22 stimulus, which might also provide protection from contact skin allergy.
To elaborate how the immune system of healthy, non-allergic individuals deals with allergens, we studied a large cohort of donors and-in line with a recently postulated concept 44 -found that nonallergic subjects do not display immunological ignorance, but react by mounting "healthy" immune reactions. 45 
| PROPHYL A XIS VS THER APY
In After the initial immunological bias is set, this is guaranteed due to natural exposure to the respective allergen(s). 6 Clearly, testing prophylactic allergy vaccinations in the clinics would require careful selection of young children with a highly predictable risk to develop type I allergy. Besides adducing family anamnesis, diagnosis of certain food allergies during the first years of life, 49 and of allergic reactions to so-called primary sensitizers, 50 identification of susceptibility genes for allergy and asthma 51 provides a basis for delimitation of candidate individuals.
Whereas genetic vaccines for allergy prevention most likely
would act by inducing pro-inflammatory immune reactions, preventive treatment of children by oral or sublingual administration of allergen(s) was already performed with the aim to induce regulatory responses. Sublingual administration of a mixture of allergen extracts from house-dust mite, cat, and timothy grass to high-risk children at an age of 12-30 months failed to induce regulatory T cells against the allergens delivered via the mucosa. 52 The authors speculated that instead of promoting tolerance, the intervention did not trigger immunologic processes at all or only worked as a weak booster. As infants are not capable of holding the allergen drops under the tongue for up to 3 minutes, the allergen concentration at the mucosal surface might have been too low and the exposure time too short for tolerogenic mucosal DCs to acquire enough allergen. Oral administration of house-dust mite extract in high-risk children below 1 year of age lacking skin test reactivity to common allergens resulted in reduced sensitization to any common allergen, but not to house-dust mite. 53 In contrast, 2-to 5-year-old children sensitized against house-dust mite and/or grass pollen treated by sublingual immunotherapy with the respective extract showed an upregulation of specific IgG and IL-10-associated function of regulatory T cells in vitro, whereas specific IgE and skin prick test reactivity remained comparable to the placebo group. 54 These data indicate that induction of allergen-specific regulatory T-cell responses sufficient to prevent allergic sensitization is a difficult task and that additional "pro-inflammatory" approaches including genetic vaccination and the use of immunomodulators such as CpG should also be taken into consideration. Notably, for prevention of allergies timing of intervention seems to be crucial: High-risk infants between 4 and 11 months of age consuming at least 6 g of peanut protein
per week until 60 months displayed a significantly reduced rate of peanut allergy compared to those avoiding peanuts. 55 It has been suggested that using defined recombinant allergens or derivatives thereof combined with optimized dosage and timing for oral tolerance induction in children could provide a powerful measurement in allergy prevention. sensitized to mountain cedar displayed a conversion of skin test from positive to negative. 58 However, as skin prick tests at the time-point of enrollment and at the study end-point were performed using allergen extracts, it is difficult to assess whether treatment induced any Cry j 2-specific immunological effects. Notably, three of three subjects tested positive for Cry j 2 at screening were found to be skin test negative for Cry j 2 on day 132.
Approximately 300 days after the first vaccination, some of the study participants received one booster dose of 2 mg to assess longterm safety and recall immune responses. Interestingly, a substantial number of prick test conversions from positive to negative were also noted for unrelated allergens pointing to a possible bystander suppressive effect provided by T helper cells. 59 Specific IgE titers remained unchanged upon immunization with the Cry j 2-LAMP vaccine and unlike in the preceding mouse study, only a marginal increase in specific IgG was noted. 58 As an alternative to intramuscular injections, in a follow-up study this vaccine was also delivered intradermally using the Biojector A follow-up study was performed in which additional groups of patients were treated with house-dust mite extract alone or QβG10 alone. 67 Surprisingly, clinical effects observed in the QβG10 group were comparable to that of the QβG10 plus extract group.
Encouraged by these results, a phase IIb trial was accomplished in a large cohort of patients receiving QβG10 at a high or a low dose, respectively, without allergen. 68 Significant improvement of combined symptom and medication scores were monitored in the highdose group compared to placebo. In conjunctival provocation tests a 10-fold increase in allergen tolerance was observed. How this unspecific allergy treatment is able to ameliorate allergic symptoms is not entirely understood. With a size of 30 nm, the VLPs get readily transported to draining lymph nodes, 69 where they are phagocytosed and their CpG content can directly be delivered to the endolysosomes of plasmacytoid DCs. 70 Upon binding of CpGs to TLR9, TH-1-promoting and simultaneously TH-2-suppressing cytokines are produced. 71 In mice, it has been shown that CpG can ameliorate the asthmatic airway response by upregulating the activity of IDO (indoleamine 2,3 dioxygenase) in DCs leading to suppression of T cells. 72 A direct effect of CpG-ODN alone also perfectly fits to the hygiene hypothesis as stimulation of innate immunity by bacterial products is known to counteract allergic reactions. This is in line with our findings that healthy farmers show a tendency to mount allergen-specific regulatory responses, whereas townspeople preferentially develop inflammatory reactions. 45 However, CpGs could also directly act on mast cells as these also express TLR9. 73 Undergoing controlled glucocorticosteroid withdrawal, patients with mild-to-moderate persistent allergic asthma were treated with the same accumulating dose of QβG10 in another clinical study.
Significant improvement of all patient-reported parameters and a significantly higher forced expiratory volume compared to placebo was recorded. 74 However, when patients were treated in a further study with this compound, no significant differences between verum and placebo could be detected. 75 In this case, QβG10 turned out to be ineffective in patients with uncontrolled moderate-to-severe allergic asthma as add-on therapy to inhaled corticosteroids plus long-acting beta-agonists.
| CON CLUS IONS
Unspecific treatment as with CpG DNA lacking any allergen preparation or extract would provide the opportunity to treat different allergies with a single compound. Besides the failure to demonstrate therapeutic efficacy of this approach in certain groups of patients, it has to be kept in mind that such an allergen-free treatment might only work for allergies against ubiquitous and perennial allergens like those derived from house-dust mite. In this case, permanent contact with allergen(s) might contribute to the therapeutic effect.
Theoretically, targeting of the encoded allergen to the ly- 
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